IBDEI14U ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20288,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,20288,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,20288,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,20289,0)
 ;;=200.10^^131^1286^91
 ;;^UTILITY(U,$J,358.3,20289,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20289,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,20289,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,20289,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,20290,0)
 ;;=273.3^^131^1286^93
 ;;^UTILITY(U,$J,358.3,20290,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20290,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,20290,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,20290,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,20291,0)
 ;;=203.00^^131^1286^103
 ;;^UTILITY(U,$J,358.3,20291,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20291,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,20291,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,20291,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,20292,0)
 ;;=203.01^^131^1286^105
 ;;^UTILITY(U,$J,358.3,20292,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20292,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,20292,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,20292,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,20293,0)
 ;;=238.6^^131^1286^108
 ;;^UTILITY(U,$J,358.3,20293,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20293,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,20293,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,20293,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,20294,0)
 ;;=205.00^^131^1286^4
 ;;^UTILITY(U,$J,358.3,20294,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20294,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,20294,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,20294,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,20295,0)
 ;;=205.01^^131^1286^6
 ;;^UTILITY(U,$J,358.3,20295,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20295,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,20295,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,20295,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,20296,0)
 ;;=205.10^^131^1286^19
 ;;^UTILITY(U,$J,358.3,20296,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20296,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,20296,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,20296,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,20297,0)
 ;;=205.11^^131^1286^21
 ;;^UTILITY(U,$J,358.3,20297,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20297,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,20297,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,20297,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,20298,0)
 ;;=289.0^^131^1286^55
 ;;^UTILITY(U,$J,358.3,20298,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20298,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,20298,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,20298,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,20299,0)
 ;;=238.4^^131^1286^109
 ;;^UTILITY(U,$J,358.3,20299,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20299,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,20299,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,20299,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,20300,0)
 ;;=V58.61^^131^1286^126
 ;;^UTILITY(U,$J,358.3,20300,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20300,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,20300,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,20300,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,20301,0)
 ;;=282.49^^131^1286^117
 ;;^UTILITY(U,$J,358.3,20301,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20301,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,20301,1,5,0)
 ;;=5^Thalassemia NEC
